Attached files
| file | filename |
|---|---|
| 8-K - PHARMACYCLICS INC | form8k07380_12042009.htm |
Exhibit
99.1
Pharmacyclics
to Host Webcast and Conference Call to
discuss
clinical updates on its HDAC and BTK program as presented at the
American
Society of Hematology Meeting Dec. 6 & 7
Sunnyvale,
CA., December 3, 2009 - Pharmacyclics, Inc. (NASDAQ: PCYC), a biopharmaceutical
company focused on developing and commercializing innovative small molecule
drugs for the treatment of immune mediated diseases and cancer, today announced
that it will host a webcast and conference call on, Tuesday, December 8, 2009 at
11:00am Eastern Time (10:00am Central Time and 8:00am Pacific Time) to discuss
clinical data regarding its HDAC Program (PCI-24781) and its BTK Program
(PCI-32765) that will be presented at the American Society of Hematology (ASH)
meeting.
Date:
December 8, 2009
Time:
11:00AM ET (10:00AM CT and 8:00AM PT)
Listen
via Internet: http://ir.pharmacyclics.com/events.cfm
Toll-free:
(877) 700-2945
International:
(706) 643-1591
Conference
ID: 45071660
A webcast
replay will be available on the Pharmacyclics website for 30 days.
The
following Posters will be presented at ASH:
Title:
Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum
Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory
Lymphoma
Date /
Time: Sunday, December 6, 2009, 6:00PM-8:00PM
Location:
Hall E (Ernest N. Morial Convention Center) Poster Board II-702
Poster
Session: Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models
Poster II
Primary
presenter: Dr. Andrew Evens, Northwestern University
Title: A
Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and
Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe
Pharmacodynamic Assay
Date /
Time: Monday, December 7, 2009, 6:00 PM-8:00 PM
Location:
Hall E (Ernest N. Morial Convention Center) Poster Board III-649
Poster
Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models Poster
III
Primary
presenter: Dr. Daniel Pollyea, Stanford University
About
Pharmacyclics
Pharmacyclics®
is a clinical-stage biopharmaceutical company focused on developing and
commercializing innovative small-molecule drugs for the treatment of immune
mediated disease and cancer. The purpose of the company is to create a
profitable business by generating income from products it develops, licenses and
commercializes, either with one or several potential partners or alone as may
best forward the economic interest of its stakeholders. The Company endeavors to
create novel, patentable, differentiated products that have the potential to
significantly improve the standard of care in the markets it serves. Presently,
Pharmacyclics has four product candidates in clinical development and two
product candidates in pre-clinical development. It is Pharmacyclics’ business
strategy to establish collaborations with large pharmaceutical and biotechnology
companies for the purpose of generating present and future income in exchange
for adding to their product pipelines. Pharmacyclics strives to generate
collaborations that allow it to retain valuable territorial rights and
simultaneously fast forward the clinical development and commercialization of
its products. The Company is headquartered in Sunnyvale, California and is
listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics
advances science to improve human healthcare visit us at
http://www.pharmacyclics.com.
Contact:
Ramses
Erdtmann
Vice
President of Finance
Phone:
408-215-3325